ABEONA THERAPEUTICS INC. Business Acquisition, Transaction Costs
ABEONA THERAPEUTICS INC. (ABEO) had Business Acquisition, Transaction Costs of $2.60 million as of 2025-12-31, per its 10-K filed 2026-03-17.
Financial Statements › Notes
us-gaap:BusinessAcquisitionCostOfAcquiredEntityTransactionCosts · last filed 2026-08-13
- 2025-12-31: Business Acquisition, Transaction Costs $2.60M.
- 2025-09-30: Business Acquisition, Transaction Costs $2.60M.
- 2025-06-30: Business Acquisition, Transaction Costs $2.60M.
| Period end | Business Acquisition, Transaction Costs |
|---|---|
| 2025-12-31 | $2.60M 10-K · filed 2026-03-17 |
| 2025-09-30 | $2.60M 10-Q · filed 2025-11-12 |
| 2025-06-30 | $2.60M 10-Q · filed 2026-08-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| BridgeBio Oncology Therapeutics, Inc. (BBOT) | United States | $0.320B | -3.35 |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| BioAge Labs, Inc. (BIOA) | United States | $0.333B | -11.88 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |